2. Search Result
Search Result
Results for "

amino-terminal

" in MedChemExpress (MCE) Product Catalog:

32

Inhibitors & Agonists

2

Biochemical Assay Reagents

25

Peptides

1

Inhibitory Antibodies

2

Natural
Products

1

Isotope-Labeled Compounds

Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-W012669
    Phthalaldehyde

    Phthaldialdehyde

    		 Environmental Pollutants Biochemical Assay Reagents Infection
    Phthalaldehyde (Phthaldialdehyde) reacts with proteins containing primary amines and blocked amino-terminal peptides of amino acids. Phthalaldehyde stabilizes bacterial outer membranes and cell walls, increases the optical density of bacterial cell suspensions, and inhibits bacterial lysis induced by ethylenediaminetetraacetic acid and sodium dodecyl sulfate. Phthalaldehyde exhibits bactericidal activity against Gram-negative vegetative bacteria .
    Phthalaldehyde
  • HY-P4070
    Insulin icodec

    		Insulin Receptor Metabolic Disease
    Insulin icodec is an Insulin (HY-P0035) analog that strongly but reversibly binds to albumin. Insulin icodec has long plasma half-life. Insulin icodec modulates insulin receptor activity, controls blood glucose levels, reduces HbA1c levels, and binds reversibly to human serum albumin. Insulin icodec can be used for the research of type 2 diabetes mellitus .
    Insulin icodec
  • HY-100348
    EPI-001

    		Androgen Receptor PPAR Apoptosis Cancer
    EPI-001, a selective inhibitor of Androgen Receptor (AR), targets transactivation unit 5 (Tau-5) of the AR. EPI-001 can inhibit transactivation of the AR amino-terminal domain (NTD), with an IC50 of ~6 μM. EPI-001 is also a selective modulator of PPARγ. EPI-001 is active against castration-resistant prostate cancer .
    EPI-001
  • HY-134222A
    N-Acetylserine

    N-Acetyl-L-serine

    		 Endogenous Metabolite Complement System Others
    N-Acetylserine (N-Acetyl-L-serine) is a complement pathway modulator targeting activated third complement protein (C3b) and an amino-terminal residue (an N-terminal acetylation modification group). N-Acetylserine reacts with the exposed thioester group of C3b via its hydroxyl group, thereby blocking the covalent binding of glycerol to this thioester group. N-Acetylserine widely exists in soluble proteins of mammalian cells (accounting for approximately 80% of such proteins). N-Acetylserine has a blocking property that prevents direct Edman sequencing of proteins; deblocking is achievable through trifluoroacetic acid-catalyzed N→O acetyl migration followed by β-elimination. N-Acetylserine is suitable for sequencing of proteins with N-terminal acetylserine modification .
    N-Acetylserine
  • HY-168940B
    NH2-PEG2000-COOH

    		Drug Intermediate Cancer
    NH2-PEG2000-COOH is a heterofunctional polyethylene glycol with one amino terminal group and one carboxyl terminal group. NH2-PEG2000-COOH reacts with N-succinimidyl-6-maleimidohexanoate to introduce a maleimide terminal group, followed by conjugation with thiolated RGD peptide via a thiol-maleimide coupling reaction to synthesize RGD-PEG-COOH. NH2-PEG2000-COOH can be used in cancer research .
    NH2-PEG2000-COOH
  • HY-P5362
    NODAGA-LM3

    		Radionuclide-Drug Conjugates (RDCs) Somatostatin Receptor Neurological Disease Cancer
    NODAGA-LM3 is a ligand that can cross the blood-brain barrier and targets somatostatin receptor SSTR2 with high affinity (IC50 = 1.3 nM). NODAGA-LM3 does not trigger the internalization of SSTR2 and can inhibit agonist-induced internalization processes. NODAGA-LM3 shows low uptake in normal tissues such as the liver and spleen, but high uptake in the lungs and blood pool. 68Ga-labeled NODAGA-LM3 can serve as a PET imaging agent for well-differentiated neuroendocrine tumors, and is applied in studies related to small cell lung cancer and well-differentiated neuroendocrine tumors .
    NODAGA-LM3
  • HY-P2336A
    CCZ01048 TFA
    3 Publications Verification

    		 Melanocortin Receptor Cancer
    CCZ01048 TFA, a α-MSH analogue, exhibits high binding affinity to melanocortin 1 receptor (MC1R) with a Ki of 0.31 nM. CCZ01048 TFA shows rapid internalization into B16F10 melanoma cells and high in vivo stability. CCZ01048 TFA is a promising candidate for PET imaging of malignant melanoma .
    CCZ01048 TFA
  • HY-160610A
    Carbamoyl phosphate dilithium salt

    		Drug Derivative Others
    Carbamoyl phosphate dilithium salt is an antisickling agent and plays a significant role in the urea cycle. Carbamoyl phosphate dilithium salt carbamylates the amino-terminal valine residues of hemoglobin S in erythrocytes, which interferes with the sickling phenomenon. Carbamoyl phosphate dilithium salt exhibits toxicity due to the lithium cation .
    Carbamoyl phosphate dilithium salt
  • HY-P10341
    ZP3022

    		GCGR Metabolic Disease
    ZP3022 is a dual agonist of glucagon-like peptide-1 (GLP-1) and gastrin that has the ability to sustainably improve glycemic control. Additionally, ZP3022 can effectively increase β-cell mass, promote β-cell proliferation, and enhance the function of pancreatic islets. ZP3022 can be used in anti-diabetic research .
    ZP3022
  • HY-P5455
    S3 Fragment

    		LIM Kinase (LIMK) Others
    S3 Fragment is a biological active peptide. (This peptide contains the unique amino-terminal phosphorylation site of Xenopus ADF/cofilin, the LIM kinase (LIMK) phosphorylation site. LIMK1 is a key regulator of the actin cytoskeleton through its phosphorylation of ADF/cofilin at serine-3 for inactivation. This peptide is a fragment of the S3 peptide containing the serine-3 sequence of ADF/cofilin that has been widely used as an effective competitive inhibitor of LIMK1.)
    S3 Fragment
  • HY-P99527
    Vanutide cridificar

    ACC-001; PF 05236806

    		 Amyloid-β Neurological Disease
    Vanutide cridificar (ACC-001) is an aminoterminal Aβ1-7 peptide conjugate. Vanutide cridificar can be used for Alzheimer's disease (AD) research .
    Vanutide cridificar
  • HY-P11004
    A3-APO

    		Bacterial Antibiotic Infection
    A3-APO is an antimicrobial peptide. A3-APO has a significant antimicrobial activity by a dual mode of action with both membrane disintegration and intracellular target inhibition. A3-APO can deactivate bacterial toxins and increase the expression of anti-inflammatory cytokines (such as IL-4 and IL-10), without antimicrobial resistance. A3-APO accelerates burn wounds healing in mice infection model of Acinetobacter baumannii and Staphylococcus aureus .
    A3-APO
  • HY-P10472
    Azaline B

    		GnRH Receptor Endocrinology
    Azaline B is an antagonist for gonadotropin-releasing hormone (GnRH) with IC50 of 1.37 nM, Azaline B can be used in research of sex hormone-related pathological states, ovulation induction and male contraception .
    Azaline B
  • HY-P4757
    N1-Glutathionyl-spermidine disulfide

    		Parasite Others
    N1-Glutathionyl-spermidine disulfide is a substrate of trypanothione reductase .
    N1-Glutathionyl-spermidine disulfide
  • HY-P5984
    Thioether-cyclized helix B peptide, CHBP

    		mTOR Others
    Thioether-cyclized helix B peptide, CHBP can improve metabolic stability and renoprotective effect through inducing autophagy via inhibition of mTORC1 and activation of mTORC2 .
    Thioether-cyclized helix B peptide, CHBP
  • HY-P11243
    EphA4 agonist compound 23

    		Ephrin Receptor Neurological Disease
    EphA4 agonist compound 23 is a novel EphA4 agonist peptide mimic. EphA4 agonist compound 23 exhibits high affinity, high selectivity, and significant receptor activation ability. EphA4 agonist compound 23 is commonly used in the study of neurodegenerative diseases .
    EphA4 agonist compound 23
  • HY-P2434
    AP102

    		Somatostatin Receptor Neurological Disease Metabolic Disease Cancer
    AP102 is a dual SSTR2/SSTR5-specific somatostatin analog (SSA). AP102 is a disulfide-bridged octapeptide SSA containing synthetic iodinated amino acids. AP102 binds with subnanomolar affinity to SSTR2 and SSTR5 (IC50: 0.63 and 0.65 nM, respectively). AP102 does not bind to SSTR1 or SSTR3. AP102 can be used for acromegaly and neuroendocrine tumors research .
    AP102
  • HY-P5362A
    NODAGA-LM3 TFA

    		Radionuclide-Drug Conjugates (RDCs) Somatostatin Receptor Cancer
    NODAGA-LM3 TFA is a ligand that can cross the blood-brain barrier and targets somatostatin receptor SSTR2 with high affinity (IC50 = 1.3 nM). NODAGA-LM3 TFA does not trigger the internalization of SSTR2 and can inhibit agonist-induced internalization processes. NODAGA-LM3 TFA shows low uptake in normal tissues such as the liver and spleen, but high uptake in the lungs and blood pool. 68Ga-labeled NODAGA-LM3 TFA can serve as a PET imaging agent for well-differentiated neuroendocrine tumors, and is applied in studies related to small cell lung cancer and well-differentiated neuroendocrine tumors .
    NODAGA-LM3 TFA
  • HY-105168
    TAK 044

    		Endothelin Receptor Cardiovascular Disease
    TAK 044 is an antagonist of Endothelin Receptor. TAK 044 strongly inhibits ET-induced deterioration in various animal models. TAK 044 can be used in study ET-related diseases such as acute myocardial infarction,acute renal failure, acute hepatic malfunction, and subarachnoid hemorrhage .
    TAK 044
  • HY-P3924
    Agouti-Related Protein (54-82) (human)

    AGRP (54-82) (human)

    		 Melanocortin Receptor Neurological Disease
    Agouti-Related Protein (54-82) (human) (AGRP (54-82) (human)) is an amino-terminal 54-82 fragment of agouti-related protein (AGRP) .
    Agouti-Related Protein (54-82) (human)
  • HY-171261
    CID15997213

    		Virus Protease Infection
    CID15997213 is a blood-brain barrier penetrating antiviral agent. CID15997213 targets the amino-terminal domain of the VEEV nonstructural protein 2 (nsP2). CID15997213 shows alphavirus-specific antiviral effect, inhibiting VEEV and Western equine encephalitis virus .
    CID15997213
  • HY-20841
    Boc-(2S)-Gly-4-pyranoyl

    (S)-2-((tert-Butoxycarbonyl)amino)-2-(tetrahydro-2H-pyran-4-yl)acetic acid; Boc-4-Pyranoyl-Gly-OH

    		 Amino Acid Derivatives Others
    Boc-(2S)-Gly-4-pyranoyl ((S)-2-((tert-Butoxycarbonyl)amino)-2-(tetrahydro-2H-pyran-4-yl)acetic acid) is an amino-terminally protected glycine derivative that can be used to synthesize dipeptidyl peptidase IV with antidiabetic activity .
    Boc-(2S)-Gly-4-pyranoyl
  • HY-P10668
    Ac-EVKKQR-pNA

    		Dengue Virus Flavivirus Infection
    Ac-EVKKQR-pNA is a competitive chromogenic para-nitroanilide substrate corresponding to the P6-P1 segment amino-terminal to the NS2B-NS3 cleavage site but with a more reactive, hydrolytically cleavable, para-nitroanilide at the P1’ position. Ac-EVKKQR-pNA is promising for research of dengue 2 virus and flavivirus virus infection .
    Ac-EVKKQR-pNA
  • HY-100348R
    EPI-001 (Standard)

    		Reference Standards Androgen Receptor PPAR Apoptosis Cancer
    EPI-001 (Standard) is the analytical standard of EPI-001. This product is intended for research and analytical applications. EPI-001, a selective inhibitor of Androgen Receptor (AR), targets transactivation unit 5 (Tau-5) of the AR. EPI-001 can inhibit transactivation of the AR amino-terminal domain (NTD), with an IC50 of ~6 μM. EPI-001 is also a selective modulator of PPARγ. EPI-001 is active against castration-resistant prostate cancer .
    EPI-001 (Standard)
  • HY-P5329
    r8-Gly-Noxa A BH3

    		NADPH Oxidase Others
    r8-Gly-Noxa A BH3 is a biological active peptide. (This cell permeable peptide is derived from the BH3 domain (a death domain) of Noxa A, amino acid residues 17 to 36. Eight D-Arginine residues and a Glycine linker residue are added to the amino terminal of the peptide.)
    r8-Gly-Noxa A BH3
  • HY-P2380
    PAR3 (1-6) (human)

    TFRGAP

    		 Protease Activated Receptor (PAR) Inflammation/Immunology
    PAR3 (1-6) is a synthetic peptide agonist of proteinase-activated receptor 1 (PAR1) that corresponds to residues 1-6 of the amino terminal tethered ligand sequence of human PAR3 and residues 39-44 of the full-length human sequence. PAR3 (1-6) activates p42/44 MAPK signaling in fibroblasts expressing PAR1, but not PAR3, an effect that can be blocked by the PAR1 antagonist RWJ 56110.
    PAR3 (1-6) (human)
  • HY-P2075
    EMD 55068

    		Renin Endocrinology
    EMD 55068 is a renin antagonist. EMD 55068 inhibits the uptake of taurocholate .
    EMD 55068
  • HY-P10876
    mcK6A1

    		Amyloid-β Neurological Disease
    mcK6A1 is an inhibitor for the aggregation of amyloid-β (Aβ), that selectively binds to the 16KLVFFA21 segment of Aβ42, forms an extended β-folded structure, and inhibits the formation of Aβ42 oligomers. mcK6A1 can be used in research of Alzheimer's disease and other amyloid-related diseases .
    mcK6A1
  • HY-P5984A
    Thioether-cyclized helix B peptide, CHBP TFA

    		mTOR Others
    Thioether-cyclized helix B peptide, CHBP (TFA) is the TFA form of Thioether-cyclized helix B peptide, CHBP (HY-P5984). Thioether-cyclized helix B peptide, CHBP (TFA) can improve metabolic stability and renoprotective effect through inducing autophagy via inhibition of mTORC1 and activation of mTORC2 .
    Thioether-cyclized helix B peptide, CHBP TFA
  • HY-W012669S
    Phthalaldehyde-d4

    Phthaldialdehyde-d4

    		 Isotope-Labeled Compounds Bacterial Infection
    Phthalaldehyde-d4 (Phthaldialdehyde-d4) is the deuterium labeled Phthalaldehyde (HY-W012669). Phthalaldehyde reacts with proteins containing primary amines and blocked amino-terminal peptides of amino acids. Phthalaldehyde stabilizes bacterial outer membranes and cell walls, increases the optical density of bacterial cell suspensions, and inhibits bacterial lysis induced by ethylenediaminetetraacetic acid and sodium dodecyl sulfate. Phthalaldehyde exhibits bactericidal activity against Gram-negative vegetative bacteria.
    Phthalaldehyde-d4
  • HY-P11488
    JR11-PEG3-DOTA-PSMA-03

    		Radionuclide-Drug Conjugates (RDCs) Somatostatin Receptor PSMA Cancer
    JR11-PEG3-DOTA-PSMA-03 (Compound 2) is an RDC-related compound containing the chelating agent DOTA (HY-W053583), the JR11 peptide (SSTR2 antagonist), and the PSMA ligand. JR11-PEG3-DOTA-PSMA-03 shows SSTR2-binding affinities and PSMA-binding affinities, with IC50 s of 94.0 nM, 81.8 nM, respectively. JR11-PEG3-DOTA-PSMA-03 can be radiolabeled with [ 68Ga]. [ 68Ga] radiolabeled JR11-PEG3-DOTA-PSMA-03 can be used in diagnostic studies of neuroendocrine differentiated prostate cancer .
    JR11-PEG3-DOTA-PSMA-03
  • HY-P11485
    JR11-PEG3-HBED-CC-PSMA-03

    		Radionuclide-Drug Conjugates (RDCs) Somatostatin Receptor PSMA Cancer
    JR11-PEG3-HBED-CC-PSMA-03 (Compound 1) is an RDC-related compound containing the chelating agent HBED-CC, the JR11 peptide (SSTR2 antagonist), and the PSMA ligand. JR11-PEG3-HBED-CC-PSMA-03 shows SSTR2-binding affinities and PSMA-binding affinities, with IC50 s of 59.2 nM, 57.0 nM, respectively. JR11-PEG3-HBED-CC-PSMA-03 can be radiolabeled with [ 68Ga]. [ 68Ga] radiolabeled JR11-PEG3-HBED-CC-PSMA-03 can be used in diagnostic studies of neuroendocrine differentiated prostate cancer .
    JR11-PEG3-HBED-CC-PSMA-03

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

  

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

  

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: